MX2012002385A - Inhibidores macrociclicos de cinasa janus. - Google Patents

Inhibidores macrociclicos de cinasa janus.

Info

Publication number
MX2012002385A
MX2012002385A MX2012002385A MX2012002385A MX2012002385A MX 2012002385 A MX2012002385 A MX 2012002385A MX 2012002385 A MX2012002385 A MX 2012002385A MX 2012002385 A MX2012002385 A MX 2012002385A MX 2012002385 A MX2012002385 A MX 2012002385A
Authority
MX
Mexico
Prior art keywords
jak
macrocyclic inhibitors
macrocyclic
inhibitors
immune
Prior art date
Application number
MX2012002385A
Other languages
English (en)
Inventor
Alam Jahangir
Michael Soth
Stephen M Lynch
Hanbiao Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012002385A publication Critical patent/MX2012002385A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Abstract

La presente invención se relaciona con el uso de compuestos macrocíclicos nuevos de la fórmula (I), en donde las variables Q, Q1, Q2, Q3, y Q4 son definidas como se describió aquí, las cuales inhiben JAK y son útiles para el tratamiento de enfermedades autoinmunes e inflamatorias.
MX2012002385A 2009-09-21 2010-09-17 Inhibidores macrociclicos de cinasa janus. MX2012002385A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24421609P 2009-09-21 2009-09-21
US37296910P 2010-08-12 2010-08-12
PCT/EP2010/063682 WO2011033053A1 (en) 2009-09-21 2010-09-17 Macrocyclic inhibitors of jak

Publications (1)

Publication Number Publication Date
MX2012002385A true MX2012002385A (es) 2012-04-02

Family

ID=43034482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002385A MX2012002385A (es) 2009-09-21 2010-09-17 Inhibidores macrociclicos de cinasa janus.

Country Status (11)

Country Link
US (1) US8318764B2 (es)
EP (1) EP2480554B1 (es)
JP (1) JP5540100B2 (es)
KR (1) KR101438293B1 (es)
CN (1) CN102498113B (es)
BR (1) BR112012006176A2 (es)
CA (1) CA2771176A1 (es)
ES (1) ES2509590T3 (es)
MX (1) MX2012002385A (es)
RU (1) RU2012116003A (es)
WO (1) WO2011033053A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104023728B (zh) * 2011-09-30 2016-11-02 益普生制药股份有限公司 大环lrrk2激酶抑制剂
CN102617599B (zh) * 2012-04-10 2014-04-16 江苏先声药物研究有限公司 大环类化合物及其应用
US9165142B1 (en) * 2013-01-30 2015-10-20 Palo Alto Networks, Inc. Malware family identification using profile signatures
WO2018153546A1 (en) * 2017-02-27 2018-08-30 Laboratorios Del Dr. Esteve, S.A. Tetrahydropyran and tetrahydrothiopyran methanone derivatives having multimodal activity against pain
US10764309B2 (en) 2018-01-31 2020-09-01 Palo Alto Networks, Inc. Context profiling for malware detection
US11159538B2 (en) 2018-01-31 2021-10-26 Palo Alto Networks, Inc. Context for malware forensics and detection
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN113735856A (zh) * 2020-05-29 2021-12-03 百极弘烨(南通)医药科技有限公司 大环jak抑制剂及其应用
US11956212B2 (en) 2021-03-31 2024-04-09 Palo Alto Networks, Inc. IoT device application workload capture
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
AU756838B2 (en) 1998-03-04 2003-01-23 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
WO2005030776A1 (en) 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
AU2007315234A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
CN101568540A (zh) * 2006-11-01 2009-10-28 沃泰克斯药物股份有限公司 用作janus激酶抑制剂的三环杂芳基化合物
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
PE20110223A1 (es) 2008-06-10 2011-05-07 Abbvie Inc DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA

Also Published As

Publication number Publication date
KR20120068940A (ko) 2012-06-27
KR101438293B1 (ko) 2014-09-05
ES2509590T3 (es) 2014-10-17
EP2480554B1 (en) 2014-08-06
US8318764B2 (en) 2012-11-27
JP5540100B2 (ja) 2014-07-02
CN102498113A (zh) 2012-06-13
WO2011033053A1 (en) 2011-03-24
EP2480554A1 (en) 2012-08-01
BR112012006176A2 (pt) 2015-09-08
CA2771176A1 (en) 2011-03-24
RU2012116003A (ru) 2013-10-27
CN102498113B (zh) 2014-11-26
US20110071179A1 (en) 2011-03-24
JP2013505219A (ja) 2013-02-14

Similar Documents

Publication Publication Date Title
MX2010008198A (es) Inhibidores de cinasa de pirrolopirazina.
PL2250172T3 (pl) Pirolopirazynowe inhibitory kinazy
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
MX2012002385A (es) Inhibidores macrociclicos de cinasa janus.
MX2014002442A (es) Inhibidores de pirrolopirazina cinasa.
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
MX2012002641A (es) Inhibidores de cinasa janus (jak).
WO2011117145A3 (en) Pyrrolopyrazine kinase inhibitors
ATE522534T1 (de) Pyrrolopyrazin-kinasehemmer
MX343561B (es) Compuestos de imidazolpiridazina.
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
MX342310B (es) Compuestos de tiazolopirimidina.
MX352928B (es) Compuestos de piridazina-amida.
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
MX2012008874A (es) Macrociclos como inhibidores del factor de coagulacion (fxia).
MY160468A (en) Novel amino azaheterocyclic carboxamides
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
GEP20135964B (en) Inhibitors of beta-secretase
IN2012DN00869A (es)
MX353257B (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
MX2011011272A (es) Procesos e intermediarios.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MX349548B (es) Compuestos de tienopirimidina.
MX2012007341A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.

Legal Events

Date Code Title Description
FG Grant or registration